Literature DB >> 23664154

Painful Na-channelopathies: an expanding universe.

Stephen G Waxman1.   

Abstract

The universe of painful Na-channelopathies--human disorders caused by mutations in voltage-gated sodium channels--has recently expanded in three dimensions. We now know that mutations of sodium channels cause not only rare genetic 'model disorders' such as inherited erythromelalgia and channelopathy-associated insensitivity to pain but also common painful neuropathies. We have learned that mutations of NaV1.8, as well as mutations of NaV1.7, can cause painful Na-channelopathies. Moreover, recent studies combining atomic level structural models and pharmacogenomics suggest that the goal of genomically guided pain therapy may not be unrealistic.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23664154     DOI: 10.1016/j.molmed.2013.04.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  27 in total

Review 1.  Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms?

Authors:  Ru-Rong Ji
Journal:  Pulm Pharmacol Ther       Date:  2015-09-06       Impact factor: 3.410

Review 2.  [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment].

Authors:  K Doppler; C Sommer
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

3.  Chemoselective tarantula toxins report voltage activation of wild-type ion channels in live cells.

Authors:  Drew C Tilley; Kenneth S Eum; Sebastian Fletcher-Taylor; Daniel C Austin; Christophe Dupré; Lilian A Patrón; Rita L Garcia; Kit Lam; Vladimir Yarov-Yarovoy; Bruce E Cohen; Jon T Sack
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

4.  Shared and unique aspects of ligand- and voltage-gated ion-channel gating.

Authors:  Derek Bowie
Journal:  J Physiol       Date:  2018-05-15       Impact factor: 5.182

5.  [Pain and analgesia : Mutations of voltage-gated sodium channels].

Authors:  M J Eberhardt; A Leffler
Journal:  Schmerz       Date:  2017-02       Impact factor: 1.107

Review 6.  Neuroimmune modulation of pain and regenerative pain medicine.

Authors:  Thomas Buchheit; Yul Huh; William Maixner; Jianguo Cheng; Ru-Rong Ji
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

7.  Control of Neurotransmission by NaV1.7 in Human, Guinea Pig, and Mouse Airway Parasympathetic Nerves.

Authors:  Michaela Kocmalova; Marian Kollarik; Brendan J Canning; Fei Ru; R Adam Herbstsomer; Sonya Meeker; Silvia Fonquerna; Monica Aparici; Montserrat Miralpeix; Xian Xuan Chi; Baolin Li; Ben Wilenkin; Jeff McDermott; Eric Nisenbaum; Jeffrey L Krajewski; Bradley J Undem
Journal:  J Pharmacol Exp Ther       Date:  2017-01-30       Impact factor: 4.030

Review 8.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 9.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

10.  What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013.

Authors:  Christopher H Fry; Arun Sahai; Bahareh Vahabi; Anthony J Kanai; Lori A Birder
Journal:  Neurourol Urodyn       Date:  2014-01-16       Impact factor: 2.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.